About us
The World's Best Non-Invasive Liquid Biopsy for Brain Tumors from Datar Genetics Limited, India Primary Central Nervous System (CNS) malignancies are a great clinical challenge due to their aggressive nature and low survival rates. Conventional disease monitoring tools such as imaging are limited in detection of tumors that are a minimum 1-2 cm in dimensions. CNS biopsies are invasive and high risk. Gliotrack is a non-invasive Liquid Biopsy blood test for brain tumors that detects presence of glioma with ultra-high precision, specificity and reliability. Gliotrack detects much lower size of malignant lesion and also gives therapy guidance. It provides information to treating Doctor to establish diagnosis, disease prognostication, stratification of patients, therapy selection and monitoring disease progression. Gliotrack detects ctDNA, mRNA and microRNA released by tumor cells in peripheral blood of the patient. Cell-free DNA released by the tumor contains all variants present in the tumor, allowing precise non-invasive monitoring of cancer in real time. Gliotrack analysis is performed on 10-20 ml of blood and result is provided in 4-5 working days of receipt of sample. Gliotrack is suitable for: • Diagnosed Glioma patients – To select therapy or to monitor therapy response • Patients with glioma who are unfit for biopsy • Patients with suspected glioma on MRI • Patients in remission – to detect recurrence at the earliest. • Patients on treatment – to distinguish disease progression from treatment associated changes and to monitor residual disease. Gliotrack Report can reveal: • Grade of disease and assessment of disease burden • Response to chemotherapy and targeted therapy drugs • Diagnosis of disease recurrence / progression. • Distinguishing primary glioblastoma from secondary glioblastoma • Chemotherapy and radiotherapy resistance associated markers • Biomarkers tested (cfDNA and exosomes)
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Type
- Privately Held